Want to see IN:AARTIDRUGS full AI Analyst Report?
Aarti Drugs Limited (AARTIDRUGS) Stock Price & Analysis
AARTIDRUGS Stock Chart & Stats
- Day’s Range
- INR 433.10 - INR 448.15
- 52-Week Range
- INR 318.60 - INR 533.60
- Previous Close
- INR 448.95
- Volume
- 68.36K
- Average Volume (3M)
- 22.12K
- Market Cap
- INR 39.77B
- Enterprise Value
- INR 34.83B
- Total Cash (Recent Filing)
- INR 242.80M
- Total Debt (Recent Filing)
- INR 5.77B
- Price to Earnings (P/E)
- 20.8
- Beta
- 1.01
- Next Earnings
- Nov 03, 2026 (Est.)
- EPS Estimate
- 7.4
- Last Dividend Ex-Date
- Feb 09, 2026
- Dividend Yield
- 0.46%
Bulls Say, Bears Say
Bulls Say
Improving Balance Sheet
Lower leverage and a steadily expanding equity base improve financial flexibility and reduce balance-sheet strain. This gives Aarti Drugs greater capacity to support operations, absorb business variability, and fund selected growth initiatives over the next several quarters.
Positive Operating Cash Flow
Positive operating cash flow indicates that the core business is generating cash from operations, providing an important internal funding base. While conversion into free cash flow is imperfect, this underlying cash generation supports ongoing business continuity and investment.
Recent Revenue Rebound
The recent return to revenue growth suggests demand and commercial activity have regained some momentum after a weaker period. If maintained, improving top-line performance can support better capacity utilization, product mix, and operating leverage across the business.
Bears Say
Margin Compression
The substantial decline in net margin shows that earnings quality is weaker than at the company’s earlier peak. Persistent pricing or cost pressure could limit profit growth even if revenue improves, reducing the business’s ability to compound earnings consistently.
Broadly Flat Revenue Trend
A largely stagnant multi-year revenue base indicates that expansion has not yet become consistently durable. Continued reliance on a modest rebound could constrain scale benefits, limit operating leverage, and make sustained earnings growth more difficult over the medium term.
Weak Free-cash-flow Conversion
Repeated weakness in free cash flow means accounting profits are not consistently converting into funds available for debt reduction, reinvestment, or shareholder returns. The volatility may reflect working-capital needs or ongoing investment, but it reduces financial self-funding visibility.
Aarti Drugs Limited News
AARTIDRUGS FAQ
What was Aarti Drugs Limited’s price range in the past 12 months?
What is Aarti Drugs Limited’s market cap?
When is Aarti Drugs Limited’s upcoming earnings report date?
How were Aarti Drugs Limited’s earnings last quarter?
Is Aarti Drugs Limited overvalued?
Does Aarti Drugs Limited pay dividends?
What is Aarti Drugs Limited’s EPS estimate?
How many shares outstanding does Aarti Drugs Limited have?
What happened to Aarti Drugs Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Aarti Drugs Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Aarti Drugs Limited
Operating both within India and globally, Aarti Drugs Limited, along with its affiliated companies, specializes in the pharmaceutical sector. Its product portfolio encompasses a wide range of active pharmaceutical ingredients (APIs) across numerous therapeutic areas, such as anti-inflammatory, cardiovascular protection, antidiarrheal, antifungal, anti-arthritis/osteoporosis, antibiotic, antidiabetic, Alzheimer's disease management, sedative, vitamin, and alcoholism treatment. Additionally, it supplies pharmaceutical intermediate compounds, including tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. Furthermore, the company manufactures and distributes various specialty chemicals. These include a comprehensive list of compounds such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, sodium benzene sulfinate, para toluene sulphonyl hydrazide, benzene sulphonic acid and its sodium salt, benzyl nicotinate, bisphenol C, bisphenol C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. Aarti Drugs also maintains a robust development pipeline, featuring products such as Acamprosate, intended for treating alcoholism; Dabigatran, an anticoagulant; Sevelamer, for managing hyperphosphatemia; Colesevelam, aimed at lowering cholesterol; Dronedarone and Olmesartan, both for cardiovascular disease treatment; Valsartan, which acts as a cardioprotectant; and Sitagliptin, an antidiabetic agent. Moreover, the firm provides contract manufacturing solutions. Established in 1984, the company's main operations are based in Mumbai, India.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Prakash Moreshwar Patil
- Employees
- 1,064
- Website
- www.aartidrugs.co.in
- Address
- Mahendra Industrial Estate, Mumbai, MA, 400 022, IN
Aarti Drugs Limited (AARTIDRUGS) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 3 | 4 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 12 | 0 | 0 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| IN:GRANULESGranules India Limited | ||
| IN:HIKALHikal Limited | ||
| IN:IOLCPIOL Chemicals & Pharmaceuticals Ltd. | ||
| IN:NEULANDLABNeuland Laboratories Ltd. | ||
| IN:SOLARASolara Active Pharma Sciences Ltd. |